The efficacy of small molecule PD-1/PD-L1 inhibitors in implementing a combination of immunotherapy and HER2-targeted therapy to enhance the potency of BC treatment should also be investigated [141,142,143,144]. This evidence concerns the gene ERBB2 and breast cancer.